Development of a novel metastatic breast cancer score based on hyaluronic acid metabolism

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  El Mezayen, Hatem A ^a   Toson, El Shahat A ^b   Darwish, Hossam ^c   Metwally, Fatheya M ^d  

^a Helwan University   (Egypt)

^b Damietta University   (Egypt)

^c Damietta Cancer Institute   (Egypt)

^d NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Biomarkers; Breast cancer; Glycosaminoglycans; Hyaluronic acid; Metastases

Indexed keywords

BETA GLUCURONIDASE; CA 15-3 ANTIGEN; GLUCOSAMINE; GLUCURONIC ACID; HYALURONIC ACID; HYALURONIDASE; N ACETYL BETA GLUCOSAMINIDASE; MUCIN 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; COLORIMETRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; AREA UNDER THE CURVE; BLOOD; BREAST TUMOR; CANCER STAGING; CLASSIFICATION; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AREA UNDER CURVE; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYALURONIC ACID; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; NEOPLASM STAGING; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84880581262     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0404-8     Document Type: Article

References (39)

1. Sahin AA, Guray M, Hunt KK. Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer. Arch Pathol Lab Med. 2009;133:869-78.
2. Perey L, Hayes DF, Maimonis P, et al. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res. 1992;52:2563-8.
3. Tsuchiya A, Kanno M, Kawaguchi T, et al. Prognostic relevance of Tn expression in breast cancer. Breast Cancer. 1999;6:175-80.
4. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-78.
5. Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6:2397-404.
6. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277:4589-92.
7. Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem. 2002;277:4593-6.
8. Pirinen R, Tammi R, Tammi M, et al. Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer. 2001;95:12-7.
9. Lokeshwar VB, Rubinowicz D, Schroeder GL, et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem. 2001;276:11922-32.
10. Slevin M, Krupinski J, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest. 1998;78:987-1003.
11. Liu N, Lapcevich RK, Underhill CB, et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res. 2001;61:1022-8.
12. Udabage L, Brownlee GR, Stern R, Brown TJ. Inhibition of hyaluronan degradation by dextran sulphate facilitates characterisation of hyaluronan synthesis: an in vitro and in vivo study. Glycoconj J. 2004;20:461-71.
13. Tanabe KK, Nishi T, Saya H. Novel variants of CD44 arising from alternative splicing: changes in the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells treated with hyaluronidase. Mol Carcinog. 1993;7:212-20.
14. El-Mezayen HA, Toson el SA, Darwish H, El-Badry E. Discriminant function based on parameters of hyaluronic acid metabolism and nitric oxide to differentiate metastatic from non-metastatic colorectal cancer patients. Tumour Biol. 2012;33:995-1004
15. Hutterer F. Degradation of mucopolysaccharides by hepatic lysosomes. Biochim Biophys Acta. 1966;115:312-9.
16. Pugh D, Leaback DH, Walker PG. Studies on glucosaminidase; N-acetyl-beta-glucosaminidase in rat kidney. Biochem J. 1957;65:464-9.
17. Goldbarg JA, Pineda EP, Banks BM, Rutenburg AM. A method for the colorimetric determination of beta-glucuronidase in urine, serum, and tissue; assay of enzymatic activity in health and disease. Gastroenterology. 1959;36:193-201.
18. Boas NF. Method for the determination of hexosamines in tissues. J Biol Chem. 1953;204:553-63.
19. Nir I. Determination of glucuronic acid by naphthoresorcinol. Anal Biochem. 1964;8:20-3.
20. Fidler IJ. 7th Jan Waldenstrom Lecture. The biology of human cancer metastasis. Acta Oncol. 1991;30:668-75.
21. Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer. 2012;117:1197-1209.
22. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000;26:91-102.
23. Molina R, Jo J, Filella X, et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 1999;19:2551-5.
24. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2012;411:1869-1874.
25. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006;66:10233-7.
26. Kumar S, West DC, Ponting JM, Gattamaneni HR. Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer. 1989;44:445-8.
27. Yabushita H, Iwasaki K, Kanyama K, et al. Clinicopathological role of serum-derived hyaluronan-associated protein (SHAP)-hyaluronan complex in endometrial cancer. Obstet Gynecol Int. 2012;2011:739150
28. Zhang L, Underhill CB, Chen L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res. 1995;55:428-33.
29. Yabushita H, Noguchi M, Kishida T, et al. Hyaluronan synthase expression in ovarian cancer. Oncol Rep. 2004;12:739-43.
30. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14:34-44.
31. Franzmann EJ, Schroeder GL, Goodwin WJ, et al. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer. 2003;106:438-45.
32. Ekici S, Cerwinka WH, Duncan R, et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer. 2004;112:121-9.
33. Liu D, Pearlman E, Diaconu E, et al. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci USA. 1996;93:7832-7.
34. Luqmani Y, Temmim L, Memon A, et al. Measurement of serum N-acetyl beta glucosaminidase activity in patients with breast cancer. Acta Oncol. 1999;38:649-53.
35. Severini G, Diana L, Di Giovannandrea R, Tirelli C. A study of serum glycosidases in cancer. J Cancer Res Clin Oncol. 1995;121:61-3.
36. Ohta H, Ono M, Sekiya C, Namiki M. Serum immunoreactive beta-glucuronidase determined by an enzyme-linked immunosorbent assay in patients with hepatic diseases. Clin Chim Acta. 1992;208:9-21.
37. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99-108.
38. Friedmann Y, Vlodavsky I, Aingorn H, et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol. 2000;157:1167-75.
39. Fieber C, Baumann P, Vallon R, et al. Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J Cell Sci. 2004;117:359-67.